March 18, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
“We are both pleased and honored to have Dr. Tripathy join our board of advisors at such meaningful moment in the expansion of Zetagen’s oncology pipeline,” said Joe C. Loy, CEO of Zetagen. “Dr. Tripathy’s expertise and proven track record of success in developing novel therapeutics for the treatment of breast cancer will be valued as we advance our novel therapy, ZetaMet™ and other oncologic candidates through clinical development. We look forward to working with and learning from him.”
Dr. Tripathy has led pivotal clinical trials supporting the approval of biological therapies for breast cancer patients, specifically targeting the HER2 oncogene and cyclin-dependent kinases (CDKs), both of which demonstrated improved patient survival. He has published a significant volume of original and landmark research in the field of breast cancer. Dr. Tripathy’s research focuses on assessing and developing novel therapeutics in breast cancer, specifically those targeting sensitivity and resistance mechanisms to growth factors, endocrine modulators, and cell cycle control pathways. He also evaluates biomarkers which predict sensitivity and resistance.
Dr. Tripathy received his medical degree from Duke University School of Medicine. He completed his residency at Duke University and fellowship at the Cancer Research Institute at the University of California, San Francisco. He has been Professor and Chairman of Breast Medical Oncology at MD Anderson Cancer Center since 2014.
ZetaMet™ (Zeta-BC-003) is a synthetic, small molecule delivered via a proprietary controlled release carrier being developed to resolve metastatic bone lesions, inhibiting pain while regenerating bone, with the potential to increase survival rates. Zetagen has discovered a new mechanism of action (MOA) for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions. ZetaMet™ (Zeta-BC-003) was granted FDA Breakthrough Designation and is in Phase 2a clinical trial for treatment of metastatic breast cancer lesions to bone as part of advanced stage cancer therapy.
Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs which may provide increased survival rates.
The company's ‘Zeta” platform encompasses the following oncological drug candidates ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).
Zetagen is presently enrolling for two clinical trials, ZetaFuse® (Zeta-ZF-002) for DDD for cervical fusion and ZetaMet™ (Zeta-BC-003) for the treatment of metastatic breast cancer lesions to the spine. To learn more, visit www.clinicaltrials.gov or www.zetagen.com.
Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Email: elizabeth.harness@mogandspringer.com
Phone: +1-585-435-7379